SCHEMBL19957934

SCHEMBL19957934

CC(C)CCCC(C)C1CCC2C3CC[C@@]4(C)CC(N)CCC4(C)C3CCC12C

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.65
CYP2C19 P33261 1/20 0.65
INPP5D Q92835 2/20 0.64
NPC1L1 Q9UHC9 5/20 0.63
POLA1 P09884 2/20 0.57
TOP2A P11388 1/20 0.57
TOP2B Q02880 1/20 0.57
USP2 O75604 2/20 0.56
LMNA P02545 2/20 0.56
MEN1 O00255 1/20 0.56
TP53 P04637 1/20 0.56
KMT2A Q03164 1/20 0.56
SRD5A1 P18405 4/20 0.50
SRD5A2 P31213 3/20 0.50
FNTA P49354 2/20 0.48
FNTB P49356 2/20 0.48
CDC25A P30304 3/20 0.47
CDC25B P30305 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12806705 0.87 POLA1 (0.74) CYP2D6CYP2C19INPP5DNPC1L1POLA1
SCHEMBL19494787 0.85 NPC1L1 (0.56) CYP2D6CYP2C19INPP5DNPC1L1POLA1
SCHEMBL27573811 0.84 NPC1L1 (0.62) CYP2D6CYP2C19INPP5DNPC1L1POLA1
SCHEMBL17817335 0.81 CYP2D6 (0.76) CYP2D6CYP2C19INPP5DNPC1L1POLA1
SCHEMBL17817080 0.81 NPC1L1 (0.82) CYP2D6CYP2C19INPP5DNPC1L1POLA1
SCHEMBL18071941 0.80 NPC1L1 (0.59) CYP2D6CYP2C19INPP5DNPC1L1POLA1
SCHEMBL24104745 0.79 NPC1L1 (0.83) CYP2D6CYP2C19INPP5DNPC1L1USP2
SCHEMBL8492231 0.79 NPC1L1 (0.67) CYP2D6CYP2C19INPP5DNPC1L1POLA1
SCHEMBL17817325 0.79 NPC1L1 (0.83) CYP2D6CYP2C19INPP5DNPC1L1USP2
SCHEMBL17817328 0.79 NPC1L1 (0.83) CYP2D6CYP2C19INPP5DNPC1L1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3293195-A1 COMPOUNDS FOR USE IN TREATING DIABETES OHR Pharmaceutical, Inc. (US) 2018-03-14 EP disclosed